Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
| ▸ | Q9HBH1 | 1/20 | 0.44 | |
| ▸ | BMP1 | P13497 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4956784 | 1.00 | CA2 (0.55) | CA2MAPK1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL1191020 | 1.00 | CA2 (0.55) | CA2MAPK1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL4318257 | 0.95 | GRIK1 (0.49) | CA2MAPK1SLC1A2SLC1A1BMP1 | |
| SCHEMBL8053095 | 0.93 | GRIK1 (0.50) | CA2MAPK1SLC1A2SLC1A1BMP1 | |
| SCHEMBL8053923 | 0.93 | GRIK1 (0.50) | CA2MAPK1SLC1A2SLC1A1BMP1 | |
| SCHEMBL5053984 | 0.85 | SLC1A2 (0.49) | CA2MAPK1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL3900173 | 0.84 | CA1 (0.56) | CA2PDF | |
| SCHEMBL13333266 | 0.82 | CA2 (0.55) | CA2MAPK1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL6135706 | 0.81 | CA2 (0.42) | CA2MAPK1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL6135711 | 0.81 | CA2 (0.42) | CA2MAPK1SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276409-A1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2006-12-07 | — | — | US | claimed |
| US-6908911-B1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2005-06-21 | — | — | US | claimed |
| EP-1210330-B1 | ANTIBACTERIAL AGENTS | VERNALIS OXFORD LTD (GB) | 2005-04-20 | — | — | EP | claimed |
| US-20050014702-A1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2005-01-20 | — | — | US | claimed |
| US-6716878-B1 | BACTERICIDE, ANTIPROTOZOAL; VANCOMYCIN RESISTANT ENTEROCOCCI AND BETA-LACTAM ANTIBIOTIC-RESISTANT BACTERIA, METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; HYDROXAMIC ACID AND N-FORMYL SUBTITUTED ALKYLAMIDES | VERNALIS (OXFORD) LIMITED (GB) | 2004-04-06 | — | — | US | claimed |
| US-6503897-B1 | N-Formylhydroxylamine derivatives; veterinary medicine; grampositive and gramnegative bacteria | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2003-01-07 | — | — | US | claimed |
| US-6423690-B1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2002-07-23 | — | — | US | claimed |
| EP-1210330-A1 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2002-06-05 | — | — | EP | claimed |
| WO-2001010835-A1 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-02-15 | — | — | WO | claimed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| WO-2001010834-A9 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARM (GB) | 2001-08-09 | — | — | WO | disclosed |
| WO-2001010834-A2 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-02-15 | — | — | WO | disclosed |
| WO-2001010835-A1 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-02-15 | — | — | WO | disclosed |
| EP-1052984-A1 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-11-22 | — | — | EP | disclosed |
| WO-2000058294-A1 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-10-05 | — | — | WO | disclosed |
| WO-1999039704-A1 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276409-A1 | Antibacterial agents | CBR3, CBR1, SIGMAR1 | CA2 1194/4885MAPK1 1458/4885SLC1A3 3300/4885 |
| US-20050014702-A1 | Antibacterial agents | CBR3, CBR1, SIGMAR1 | CA2 1194/4885MAPK1 1458/4885SLC1A3 3300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.